Wednesday Nov 18 | Armchair Generalist
Story in the Washington Post yesterday talks about a new anthrax drug, intended for treatment after exposure to the disease .
Human Genome reports positive data on lupus drug
Human Genome Sciences and GlaxoSmithKline said Monday their experimental lupus treatment passed another key goal on its path to potentially becoming the first new drug for the disease in decades.
A panel of experts of the US Food and Drug Administration has recently asked for additional data to judge the efficacy of Human Genome Sciences Inc.
BioMed News Bytes: Dyax, Human Genome Sciences, Aldagen
The BioMedReports.com FDA Calendar service includes a database with over 400 entries of pending new drug, biological agent, or medical device new product decisions at the FDA ; pending new submissions to the FDA; pending complete response letter re-submissions to the FDA; and pending clinical trial results.
Questions raised about HGS anthrax vaccine
A report prepared for a Food and Drug Administration panel scheduled to consider approval of Human Genome Sciences Inc.
NIAID To Fund Development Of Emergent BioSolutions' Advanced Anthrax Vaccine Candidate
Main Category: Bio-terrorism / Terrorism Also Included In: Immune System / Vaccines Article Date: 02 Oct 2009 Emergent BioSolutions Inc.
Better immune defense against anthrax
Scientists discover a gene in anthrax-causing bacteria may help defend against this form of bio-warfare. Spread of the deadly disease anthrax by spores of the bacterium Bacillus anthracis is a known terrorism risk and protection includes finding ways to treat the disease, according to an academic paper reviewed by Faculty of 1000 .
First PersonINTERN to the Lion
First Person INTERN TO THE LION by Zett-Alexandra Scheinbaum American Reporter Correspondent Washington, D.C. WASHINGTON, D.C., Aug.
Einstein scientists move closer to a safer anthrax vaccine
Researchers at Albert Einstein College of Medicine of Yeshiva University have identified two small protein fragments that could be developed into an anthrax vaccine that may cause fewer side effects than the current vaccine.
OMRF receives grants totaling $26M
OKLAHOMA CITY The National Institutes of Health has awarded two grants worth $26.3 million to the Oklahoma Medical Research Foundation for research into anthrax and to help train new scientists.
Fear of anthrax stalks Jaldapara
Alipurduar, Aug. 17: Jaldapara Wildlife Sanctuary is gearing up for a possible anthrax attack as a rhino calf is suspected to have died of the disease yesterday.
Emergent BioSolutions: Little Risk, Potentially Huge Reward
Emergent BioSolutions traded sharply higher after releasing earnings Friday morning .
Emergent BioSolutions: Little Risk, Potentially Huge Reward
Emergent BioSolutions traded sharply higher after releasing earnings Friday morning .
I.G. Farben and Exxon, re-visited
In an earlier post on IPBiz [ Standard Oil and I.G. Farben: patents and antitrust ], the interrelationship of I.G. Farben and Standard Oil of New Jersey [now ExxonMobil] was discussed.
Customer Interaction Solutions
EBS, COMV, GFF, AMSF, ANX, OSUR Expected To Be Lower Leading Up To Next Earnings Releases
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed before their last 12 quarterly, 6 quarterly and August earnings reports.
Early detection, quick anthrax treatment can saves lives
Washington, July 25 : Early detection and quick treatment can save nearly 87pct of people affected from anthrax, finds a new study.
CBR Weapons and WMD Terrorism News, July 24, 2009
Human Genome gets new order for anthrax drug "Human Genome Sciences Inc said it received a second order for its drug ABthrax, which fights anthrax infection [sic], from the U.S. government.
Human Genome doubles quarterly revenue
Human Genome Sciences Inc. , a frequent newsmaker this week, more than doubled its quarterly revenue while shaving its quarterly losses down by 18 percent in the period from April through June, though it still fell short of analyst expectations.
Human Genome sells more anthrax drug to government
Human Genome Sciences Inc. said Wednesday the U.S. government placed an additional order for its inhaled anthrax treatment ABthrax for $151 million.
Human Genome Sciences lupus drug met study goal
Biotech drugmaker Human Genome Sciences reported positive results Monday for its experimental lupus drug, confounding analyst expectations and potentially clearing the way for the first new treatment against the inflammatory disease in a half century.
Also on Topix